Menopause & Perimenopause

01  Pathophysiology

Understand the hormonal cascade driving perimenopause and menopause, including VMS and GSM.

02  Hormonal Therapy

Apply current evidence for MHT indications, timing, formulations, and risk stratification.

03  Dietary Approaches

Evaluate phytoestrogens, Mediterranean diet, and nutritional strategies for symptom management.

04  Ancillary Therapies

Review non-hormonal pharmacologic options, CBT, acupuncture, and supplement evidence.

Ovarian Reserve ↓

Declining follicular pool → reduced inhibin B → rising FSH

Estradiol ↓↓

Hypothalamic thermoregulatory dysregulation → vasomotor instability

Progesterone ↓

Anovulatory cycles → irregular bleeding; sleep disruption

of women aged 45–55 experience VMS

median duration of bothersome hot flushes

years of VMS in some women post-menopause

VMS linked to elevated cardiovascular risk markers

Symptoms

• Vaginal dryness, burning, irritation
• Dyspareunia & decreased libido
• Urinary urgency, frequency, recurrent UTIs
• Stress urinary incontinence

Pathophysiology

• Estrogen receptors throughout urogenital tract
• Atrophy of vaginal epithelium (↑ parabasal cells)
• ↑ vaginal pH (>5.0)
• Thinning of urethral mucosa

🦴 Bone

Accelerated bone resorption; up to 20% trabecular bone loss in first 5 years post-menopause. Fracture risk rises sharply.

❤️ Cardiovascular

Loss of estrogen's cardioprotective effects: ↑ LDL, ↑ visceral fat, ↑ arterial stiffness, ↑ coronary artery disease risk.

🧠 Cognition & Mood

Sleep disruption, depressive symptoms, and verbal memory changes. "Window of opportunity" for neuroprotection.

✅ Optimal Window

Age <60 years or within 10 years of final menstrual period

Cardiovascular & cognitive benefits most likely

⚠️ Caution Zone

Age 60–65 or 10–15 years post-menopause

Individualized shared decision-making required

⛔ Late Initiation

Age >65 or >15 years post-menopause

↑ Risk of cardiovascular events & dementia; generally avoid

Transdermal (Preferred)

• Avoids first-pass hepatic metabolism
• Lower VTE risk vs. oral estrogen
• No ↑ in triglycerides
• More stable serum estradiol levels
• Preferred in women with migraine, hypertension, or VTE risk

Oral

• Convenient and well-studied
• ↑ SHBG (may reduce androgen availability)
• Small ↑ VTE risk (2–4x baseline)
• May ↑ triglycerides
• Favorable lipid effects (↑ HDL, ↓ LDL)

ET Alone

Estrogen-only therapy (post-hysterectomy) may actually reduce breast cancer risk in some analyses.

EPT (Synthetic Progestogen)

Small but real ↑ in breast cancer risk with >5 years of use. Approximately 1 additional case per 1,000 women/year.

Micronized Progesterone

May carry a lower breast cancer risk than synthetic progestogens. Preferred for women with breast cancer concerns.

Benefits (Early Initiation)

• 25–50% reduction in fatal cardiovascular events when started early (JAMA 2026 updated labeling)
• Favorable lipid profile: ↑ HDL, ↓ LDL
• Reduced visceral adiposity
• ↓ Type 2 diabetes incidence

Risks (Late Initiation)

• Oral estrogen: small ↑ VTE risk (2–4×)
• Transdermal estrogen: no significant VTE ↑
• Initiation >10 years post-menopause: ↑ coronary events
• Stroke risk: small ↑ with oral estrogen

Efficacy

• Standard-dose EPT: +4.5% lumbar spine BMD, +3.7% femoral neck BMD (WHI)
• Reduces fractures at hip, spine, and non-spinal sites
• Benefits extend even to women without osteoporosis
• Essential for women with POI until age of natural menopause

Key Caveat

• Bone protection is lost rapidly after stopping MHT
• Low-dose estrogen also improves BMD
• MHT preferred over bisphosphonates in women <60 with VMS + osteoporosis
• Annual reassessment of benefit-risk ratio recommended

Isoflavones (Soy)

• Genistein, daidzein, formononetin
• 2025 meta-analysis: modest ↓ in hot flash frequency & severity
• Safe for most women; no significant estrogenic effects on breast tissue
• 40–80 mg/day studied in trials

Lignans (Flaxseed)

• Converted to enterolactone by gut bacteria
• Weaker evidence for VMS relief
• Cardioprotective & anti-inflammatory benefits
• 1–2 tbsp ground flaxseed daily

Equol Producers

• ~30–50% of Western women convert daidzein → equol
• Equol producers show greater VMS benefit from soy
• Gut microbiome plays a key role
• Testing available but not routine

Key Components

• High: fruits, vegetables, legumes, whole grains
• Moderate: fish, poultry, dairy
• Primary fat: extra-virgin olive oil
• Low: red meat, processed foods, added sugar

Evidence for Menopause

• ↓ frequency and severity of hot flashes
• Legumes + olive oil: ↓ total menopausal symptom score
• High-fat / high-sugar diet: 23% ↑ risk of VMS
• Cardioprotective, bone-protective, anti-inflammatory

Mechanism of Action

Selectively blocks neurokinin 3 (NK3) receptors in the hypothalamic thermoregulatory center, directly reducing the neuronal signaling that triggers hot flashes — without hormonal activity.

Clinical Evidence

• SKYLIGHT 1 & 2 Phase 3 trials: significant ↓ in VMS frequency & severity
• Onset of action: within 1 week
• Dose: 45 mg once daily
• Improves sleep quality and quality of life
• Safe for women with contraindications to MHT

What CBT Targets

• Catastrophic thinking about hot flashes
• Sleep disturbance & insomnia
• Anxiety and depressive symptoms
• Perceived bother of VMS (not frequency)

Evidence

• 46% ↓ in daily interference from hot flashes (Muñiz et al., 2025)
• 28% ↓ in hot flash frequency
• Effective in-person and via digital delivery
• NAMS & NICE: recommended non-hormonal option
• Particularly useful when MHT is contraindicated

What the Evidence Shows

• Meta-analyses: ↓ VMS frequency & severity vs. no treatment
• ~40% reduction in hot flash scores in some RCTs
• Improvements in sleep quality and quality of life
• Benefits sustained for up to 6 months post-treatment

Limitations

• No significant advantage over sham acupuncture in some trials
• Strong placebo response in VMS trials
• Inconsistent protocols across studies
• NAMS: insufficient evidence to recommend routinely

Step 1: Assess

• Symptom burden (VMS, GSM, mood, sleep)
• Cardiovascular risk profile
• Personal & family cancer history
• Bone mineral density
• Patient preferences & values

Step 2: Stratify

• Age & years since menopause
• Uterus present or absent
• MHT candidate vs. non-candidate
• Identify contraindications
• Assess patient readiness for therapy

Step 3: Individualize

• Lowest effective dose
• Preferred route (transdermal preferred)
• Combine with lifestyle & dietary measures
• Reassess annually
• No arbitrary duration limit if benefits outweigh risks

What Changed (Nov 10, 2025)

• Reversed 23 years of restrictive "black box" framing
• Acknowledges 25–50% reduction in fatal cardiovascular events with early initiation
• Removes requirement to use "lowest dose for shortest time" as a universal mandate
• Supports individualized, shared decision-making

Clinical Implications

• Improved patient access to MHT
• Clinicians empowered to counsel without outdated fear-based framing
• Reinforces timing hypothesis in labeling
• ACOG commends the update as overdue

Hormonal Therapy

• MHT remains the most effective treatment for VMS
• Timing matters: initiate within 10 years of menopause
• Transdermal estrogen + micronized progesterone is preferred
• Low-dose vaginal estrogen is first-line for GSM

Dietary & Lifestyle

• Mediterranean diet reduces VMS and supports long-term health
• Soy isoflavones offer modest, safe VMS relief
• 150 min/week aerobic + resistance training is the standard
• Weight management reduces VMS severity

Non-Hormonal Options

• Fezolinetant: first-in-class NK3 antagonist; highly effective
• SSRIs/SNRIs: moderate efficacy; ideal with comorbid mood disorders
• CBT: reduces VMS bother and improves sleep

Practice Principles

• Individualized, shared decision-making is essential
• No arbitrary duration limit for MHT if benefits outweigh risks
• Annual reassessment of therapy and risk profile
• Empower patients with accurate, updated information